Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 641 entries
Sorted by: Best Match Show Resources per page
How stereotype threat affects the brain dynamics of creative thinking in female students

stereotype threat

Dickson DS, Jończyk R, Kremer GE.
GSID: RX0jOG9dfowJ
R Jończyk, DS Dickson, TS Bel-Bahar, GE Kremer… - Neuropsychologia, 2022 - Elsevier

When people are placed in a situation where they are at risk of substantiating a negative stereotype about their social group (a scenario termed stereotype threat), the extra pressure to avoid this outcome can undermine their performance. Substantial and...

Cite
Jończyk, R., Dickson, D. S., Bel-Bahar, T. S., Kremer, G. E., Siddique, Z., & van Hell, J. G. (2022). How stereotype threat affects the brain dynamics of creative thinking in female students. Neuropsychologia, 173, 108306.
Jończyk, Rafał, et al. "How stereotype threat affects the brain dynamics of creative thinking in female students." Neuropsychologia 173 (2022): 108306.
Copy Download .nbib Format: MLA
Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Nature

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.
PMID: 27007847
Nature. 2016 Jul 28;535(7613):580. doi: 10.1038/nature17642. Epub 2016 Mar 23.

No abstract available.

Cite
Caskey M, Klein F, Lorenzi JC, et al. Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2016;535(7613):580doi: 10.1038/nature17642.
Caskey, M., Klein, F., Lorenzi, J. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., Horwitz, J. A., Shimeliovich, I., Ben-Avraham, S., Witmer-Pack, M., Platten, M., Lehmann, C., Burke, L. A., Hawthorne, T., Gorelick, R. J., Walker, B. D., Keler, T., Gulick, R. M., Fätkenheuer, G., Schlesinger, S. J., & Nussenzweig, M. C. (2016). Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 535(7613), 580. https://doi.org/10.1038/nature17642
Caskey, Marina, et al. "Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117." Nature vol. 535,7613 (2016): 580. doi: https://doi.org/10.1038/nature17642
Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC. Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2016 Jul 28;535(7613):580. doi: 10.1038/nature17642. Epub 2016 Mar 23. PMID: 27007847.
Copy Download .nbib Format: NLM
Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Molecular and clinical oncology

Bachmann C, Bachmann R, Kraemer B, Brucker SY, Staebler A, Fend F, Rothmund R, Wallwiener D.
PMID: 27703680
Mol Clin Oncol. 2016 Oct;5(4):483-487. doi: 10.3892/mco.2016.982. Epub 2016 Aug 05.

The objective of this study was to examine the relevance of pelvic and para-aortic lymph node involvement and the tumour characteristics affecting nodal metastases and survival in primary advanced ovarian cancer. A total of 130 consecutive patients were retrospectively...

Cite
Bachmann C, Bachmann R, Kraemer B, et al. Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer. Mol Clin Oncol. 2016;5(4):483-487doi: 10.3892/mco.2016.982.
Bachmann, C., Bachmann, R., Kraemer, B., Brucker, S. Y., Staebler, A., Fend, F., Rothmund, R., & Wallwiener, D. (2016). Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer. Molecular and clinical oncology, 5(4), 483-487. https://doi.org/10.3892/mco.2016.982
Bachmann, Cornelia, et al. "Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer." Molecular and clinical oncology vol. 5,4 (2016): 483-487. doi: https://doi.org/10.3892/mco.2016.982
Bachmann C, Bachmann R, Kraemer B, Brucker SY, Staebler A, Fend F, Rothmund R, Wallwiener D. Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer. Mol Clin Oncol. 2016 Oct;5(4):483-487. doi: 10.3892/mco.2016.982. Epub 2016 Aug 05. PMID: 27703680; PMCID: PMC5038892.
Copy Download .nbib Format: NLM
Doubling the blockade for melanoma immunotherapy.

Oncoimmunology

Galluzzi L, Eggermont A, Kroemer G.
PMID: 26942094
Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016.

No abstract available.

Cite
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015;5(1):e1106127doi: 10.1080/2162402X.2015.1106127.
Galluzzi, L., Eggermont, A., & Kroemer, G. (2016). Doubling the blockade for melanoma immunotherapy. Oncoimmunology, 5(1), e1106127. https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi, Lorenzo, et al. "Doubling the blockade for melanoma immunotherapy." Oncoimmunology vol. 5,1 (2016): e1106127. doi: https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016. PMID: 26942094; PMCID: PMC4760293.
Copy Download .nbib Format: NLM
Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Cite
Bloy N, Buqué A, Aranda F, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531doi: 10.1080/2162402X.2015.1026531.
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 4(5), e1026531. https://doi.org/10.1080/2162402X.2015.1026531
Bloy, Norma, et al. "Trial watch: Naked and vectored DNA-based anticancer vaccines." Oncoimmunology vol. 4,5 (2015): e1026531. doi: https://doi.org/10.1080/2162402X.2015.1026531
Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. PMID: 26155408; PMCID: PMC4485755.
Copy Download .nbib Format: NLM
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Oncoimmunology

Kroemer G, Galluzzi L.
PMID: 26140249
Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul.

Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma. These...

Cite
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015;4(7):e1058037doi: 10.1080/2162402X.2015.1058037.
Kroemer, G., & Galluzzi, L. (2015). Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology, 4(7), e1058037. https://doi.org/10.1080/2162402X.2015.1058037
Kroemer, Guido, and Galluzzi, Lorenzo. "Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark." Oncoimmunology vol. 4,7 (2015): e1058037. doi: https://doi.org/10.1080/2162402X.2015.1058037
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul. PMID: 26140249; PMCID: PMC4485790.
Copy Download .nbib Format: NLM
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?.

Oncoimmunology

Kroemer G, Galluzzi L, Zitvogel L, Fridman WH.
PMID: 26140250
Oncoimmunology. 2015 Jun 05;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. eCollection 2015 Jul.

The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better...

Cite
Kroemer G, Galluzzi L, Zitvogel L, et al. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology. 2015;4(7):e1058597doi: 10.1080/2162402X.2015.1058597.
Kroemer, G., Galluzzi, L., Zitvogel, L., & Fridman, W. H. (2015). Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology, 4(7), e1058597. https://doi.org/10.1080/2162402X.2015.1058597
Kroemer, Guido, et al. "Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?." Oncoimmunology vol. 4,7 (2015): e1058597. doi: https://doi.org/10.1080/2162402X.2015.1058597
Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology. 2015 Jun 05;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. eCollection 2015 Jul. PMID: 26140250; PMCID: PMC4485723.
Copy Download .nbib Format: NLM
Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast.

Microbial cell (Graz, Austria)

Braun RJ, Sommer C, Leibiger C, Gentier RJ, Dumit VI, Paduch K, Eisenberg T, Habernig L, Trausinger G, Magnes C, Pieber T, Sinner F, Dengjel J, Leeuwen FW, Kroemer G, Madeo F.
PMID: 28357285
Microb Cell. 2015 Mar 20;2(4):136-138. doi: 10.15698/mic2015.04.199.

Impaired protein degradation and mitochondrial dysfunction are believed to contribute to neurodegenerative disorders, including Alzheimer disease (AD). In patients suffering from non-hereditary AD, UBB

Cite
Braun RJ, Sommer C, Leibiger C, et al. Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast. Microb Cell. 2015;2(4):136-138doi: 10.15698/mic2015.04.199.
Braun, R. J., Sommer, C., Leibiger, C., Gentier, R. J., Dumit, V. I., Paduch, K., Eisenberg, T., Habernig, L., Trausinger, G., Magnes, C., Pieber, T., Sinner, F., Dengjel, J., Leeuwen, F. W., Kroemer, G., & Madeo, F. (2015). Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast. Microbial cell (Graz, Austria), 2(4), 136-138. https://doi.org/10.15698/mic2015.04.199
Braun, Ralf J, et al. "Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast." Microbial cell (Graz, Austria) vol. 2,4 (2015): 136-138. doi: https://doi.org/10.15698/mic2015.04.199
Braun RJ, Sommer C, Leibiger C, Gentier RJ, Dumit VI, Paduch K, Eisenberg T, Habernig L, Trausinger G, Magnes C, Pieber T, Sinner F, Dengjel J, Leeuwen FW, Kroemer G, Madeo F. Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast. Microb Cell. 2015 Mar 20;2(4):136-138. doi: 10.15698/mic2015.04.199. PMID: 28357285; PMCID: PMC5348975.
Copy Download .nbib Format: NLM
[No title available]

Microbial cell (Graz, Austria)

Sixt BS, Valdivia RH, Kroemer G.
PMID: 28357396
Microb Cell. 2017 Mar 02;4(3):101-104. doi: 10.15698/mic2017.03.564.

Bacteria of the phylum

Cite
Sixt BS, Valdivia RH, Kroemer G. . Microb Cell. 2017;4(3):101-104doi: 10.15698/mic2017.03.564.
Sixt, B. S., Valdivia, R. H., & Kroemer, G. (2017). . Microbial cell (Graz, Austria), 4(3), 101-104. https://doi.org/10.15698/mic2017.03.564
Sixt, Barbara S, et al. "." Microbial cell (Graz, Austria) vol. 4,3 (2017): 101-104. doi: https://doi.org/10.15698/mic2017.03.564
Sixt BS, Valdivia RH, Kroemer G. . Microb Cell. 2017 Mar 02;4(3):101-104. doi: 10.15698/mic2017.03.564. PMID: 28357396; PMCID: PMC5349196.
Copy Download .nbib Format: NLM
Me, Myself and My Brain Implant: Deep Brain Stimulation Raises Questions of Personal Authenticity and Alienation.

Neuroethics

Kraemer F.
PMID: 24273619
Neuroethics. 2013;6:483-497. doi: 10.1007/s12152-011-9115-7. Epub 2011 May 12.

In this article, I explore select case studies of Parkinson patients treated with deep brain stimulation (DBS) in light of the notions of alienation and authenticity. While the literature on DBS has so far neglected the issues of authenticity...

Cite
Kraemer F. Me, Myself and My Brain Implant: Deep Brain Stimulation Raises Questions of Personal Authenticity and Alienation. Neuroethics. 2011;6:483-497doi: 10.1007/s12152-011-9115-7.
Kraemer, F. (2013). Me, Myself and My Brain Implant: Deep Brain Stimulation Raises Questions of Personal Authenticity and Alienation. Neuroethics, 6483-497. https://doi.org/10.1007/s12152-011-9115-7
Kraemer, Felicitas. "Me, Myself and My Brain Implant: Deep Brain Stimulation Raises Questions of Personal Authenticity and Alienation." Neuroethics vol. 6 (2013): 483-497. doi: https://doi.org/10.1007/s12152-011-9115-7
Kraemer F. Me, Myself and My Brain Implant: Deep Brain Stimulation Raises Questions of Personal Authenticity and Alienation. Neuroethics. 2013;6:483-497. doi: 10.1007/s12152-011-9115-7. Epub 2011 May 12. PMID: 24273619; PMCID: PMC3825521.
Copy Download .nbib Format: NLM
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial.

Geburtshilfe und Frauenheilkunde

Hahn M, Brucker S, Kraemer D, Wallwiener M, Taran FA, Wallwiener CW, Krämer B.
PMID: 26097247
Geburtshilfe Frauenheilkd. 2015 May;75(5):442-449. doi: 10.1055/s-0035-1545931.

No abstract available.

Cite
Hahn M, Brucker S, Kraemer D, et al. Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial. Geburtshilfe Frauenheilkd. 2015;75(5):442-449doi: 10.1055/s-0035-1545931.
Hahn, M., Brucker, S., Kraemer, D., Wallwiener, M., Taran, F. A., Wallwiener, C. W., & Krämer, B. (2015). Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial. Geburtshilfe und Frauenheilkunde, 75(5), 442-449. https://doi.org/10.1055/s-0035-1545931
Hahn, M, et al. "Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial." Geburtshilfe und Frauenheilkunde vol. 75,5 (2015): 442-449. doi: https://doi.org/10.1055/s-0035-1545931
Hahn M, Brucker S, Kraemer D, Wallwiener M, Taran FA, Wallwiener CW, Krämer B. Radiofrequency Volumetric Thermal Ablation of Fibroids and Laparoscopic Myomectomy: Long-Term Follow-up From a Randomized Trial. Geburtshilfe Frauenheilkd. 2015 May;75(5):442-449. doi: 10.1055/s-0035-1545931. PMID: 26097247; PMCID: PMC4461677.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 641 entries